全文获取类型
收费全文 | 202801篇 |
免费 | 14931篇 |
国内免费 | 8540篇 |
专业分类
耳鼻咽喉 | 1109篇 |
儿科学 | 4193篇 |
妇产科学 | 2147篇 |
基础医学 | 20419篇 |
口腔科学 | 2180篇 |
临床医学 | 25899篇 |
内科学 | 32960篇 |
皮肤病学 | 1548篇 |
神经病学 | 23785篇 |
特种医学 | 5156篇 |
外国民族医学 | 18篇 |
外科学 | 15246篇 |
综合类 | 36016篇 |
现状与发展 | 32篇 |
预防医学 | 10645篇 |
眼科学 | 1521篇 |
药学 | 21339篇 |
128篇 | |
中国医学 | 8793篇 |
肿瘤学 | 13138篇 |
出版年
2024年 | 425篇 |
2023年 | 2598篇 |
2022年 | 6102篇 |
2021年 | 8344篇 |
2020年 | 7348篇 |
2019年 | 6152篇 |
2018年 | 6261篇 |
2017年 | 6725篇 |
2016年 | 7452篇 |
2015年 | 7563篇 |
2014年 | 14517篇 |
2013年 | 14878篇 |
2012年 | 13341篇 |
2011年 | 14150篇 |
2010年 | 11283篇 |
2009年 | 10634篇 |
2008年 | 10581篇 |
2007年 | 10523篇 |
2006年 | 9470篇 |
2005年 | 8382篇 |
2004年 | 6911篇 |
2003年 | 6008篇 |
2002年 | 4747篇 |
2001年 | 4234篇 |
2000年 | 3635篇 |
1999年 | 3171篇 |
1998年 | 2652篇 |
1997年 | 2347篇 |
1996年 | 1944篇 |
1995年 | 1620篇 |
1994年 | 1554篇 |
1993年 | 1203篇 |
1992年 | 1073篇 |
1991年 | 1017篇 |
1990年 | 841篇 |
1989年 | 708篇 |
1988年 | 662篇 |
1987年 | 590篇 |
1986年 | 516篇 |
1985年 | 738篇 |
1984年 | 634篇 |
1983年 | 434篇 |
1982年 | 507篇 |
1981年 | 442篇 |
1980年 | 350篇 |
1979年 | 248篇 |
1978年 | 185篇 |
1977年 | 152篇 |
1976年 | 121篇 |
1975年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Saudi Pharmaceutical Journal》2022,30(11):1572-1588
Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of a metabolic syndrome caused by excessive accumulation of fat in the liver. Orthosiphon stamineus also known as Orthosiphon aristatus is a medicinal plant with possible potential beneficial effects on various metabolic disorders. This study aims to investigate the in vitro inhibitory effects of O. stamineus on hepatic fat accumulation and to further use the computational systems pharmacology approach to identify the pharmacokinetic properties of the bioactive compounds of O. stamineus and to predict their molecular mechanisms against NAFLD. Methods: The effects of an ethanolic extract of O. stamineus leaves on cytotoxicity, fat accumulation and antioxidant activity were assessed using HepG2 cells. The bioactive compounds of O. stamineus were identified using LC/MS and two bioinformatics databases, namely the Traditional Chinese Medicine Integrated Database (TCMID) and the Bioinformatics Analysis Tool for the Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM). Pathway enrichment analysis was performed on the predicted targets of the bioactive compounds to provide a systematic overview of the molecular mechanism of action, while molecular docking was used to validate the predicted targets. Results: A total of 27 bioactive compounds corresponding to 50 potential NAFLD-related targets were identified. O. stamineus exerts its anti-NAFLD effects by modulating a variety of cellular processes, including oxidative stress, mitochondrial β-oxidation, inflammatory signalling pathways, insulin signalling, and fatty acid homeostasis pathways. O. stamineus is significantly targeting many oxidative stress regulators, including JNK, mammalian target of rapamycin (mTOR), NFKB1, PPAR, and AKT1. Molecular docking analysis confirmed the expected high affinity for the potential targets, while the in vitro assay indicates the ability of O. stamineus to inhibit hepatic fat accumulation. Conclusion: Using the computational systems pharmacology approach, the potentially beneficial effect of O. stamineus in NAFLD was indicated through the combination of multiple compounds, multiple targets, and multicellular components. 相似文献
2.
3.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
4.
5.
《Archivos de bronconeumología》2022,58(3):246-254
We have updated recommendations on 12 controversial topics that were published in the 2013 National Consensus on the diagnosis, risk stratification and treatment of patients with pulmonary embolism (PE). A comprehensive review of the literature was performed for each topic, and each recommendation was evaluated in two teleconferences. For diagnosis, we recommend against using the Pulmonary Embolism Rule Out Criteria (PERC) rule as the only test to rule out PE, and we recommend using a D-dimer cutoff adjusted to age to rule out PE. We suggest using computed tomography pulmonary angiogram as the imaging test of choice for the majority of patients with suspected PE. We recommend using direct oral anticoagulants (over vitamin K antagonists) for the vast majority of patients with acute PE, and we suggest using anticoagulation for patients with isolated subsegmental PE. We recommend against inserting an inferior cava filter for the majority of patients with PE, and we recommend using full-dose systemic thrombolytic therapy for PE patients requiring reperfusion. The decision to stop anticoagulants at 3 months or to treat indefinitely mainly depends on the presence (or absence) and type of risk factor for venous thromboembolism, and we recommend against thrombophilia testing to decide duration of anticoagulation. Finally, we suggest against extensive screening for occult cancer in patients with PE. 相似文献
6.
7.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献
8.
9.
10.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献